Amgen Keeps Patents Related to PCSK9 antibodies

| By | Amgen, Drug Patents, Regeneron, Sanofi

Amgen announced that a Delaware jury delivered a verdict in Amgen’s favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen’s innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a previous trial in March 2016 where Sanofi and Regeneron admitted infringement of Amgen’s patents and where a prior jury also upheld the validity of Amgen’s patents. The prior jury decision was partially reversed on appeal and the case was remanded to the district court for a new trial on two validity issues. In today’s verdict, the jury found that the Amgen patents meet the legal requirements of written description and enablement.

Today’s decision protects intellectual property which is essential to innovators who are bringing forward new medicines for patients with serious diseases. Amgen scientists discovered and developed Repatha, which can play a key role in the fight against cardiovascular disease. We are thankful that the jury weighed the evidence carefully and recognized the validity of Amgen’s patents,

said Robert A. Bradway, chairman
and chief executive officer at Amgen.

The decision follows recent decisions in the European Patent Office and the Japanese Patent Office which also rejected challenges to the validity of Amgen’s PCSK9 antibody patents brought by Sanofi, Regeneron and other potential competitors. Amgen is seeking to enforce these patents in the national courts in Europe and Japan against Sanofi and Regeneron.

SOURCE: amgen
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.